BREAKTHROUGH THERAPIES IN TYPE 2 DIABETES: ADVANCED ROLE OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS

Authors

Ergasheva Gulshan Tokhirovna Assistant of the Department of Clinical Sciences Asian International University, Bukhara, Uzbekistan

Keywords:

Type 2 diabetes mellitus, GLP-1 receptor agonists, SGLT2 inhibitors, semaglutide, tirzepatide, cardiovascular protection, renal protection, incretin therapy

Abstract

Type 2 diabetes mellitus (T2DM) is a global health challenge characterized by chronic hyperglycemia and associated complications. Recent therapeutic breakthroughs, particularly GLP-1 receptor agonists and SGLT2 inhibitors, have transformed diabetes management. These agents not only reduce blood glucose levels but also provide cardiovascular and renal protection. This article provides a comprehensive review of their mechanisms, clinical efficacy, combination therapy, and future perspectives in modern diabetes care.

Downloads

Download data is not yet available.

References

American Diabetes Association. (2024). Standards of Medical Care in Diabetes. Diabetes Care.

Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. Nature.

DeFronzo, R. A. (2009). From the triumvirate to the ominous octet: a new paradigm for type 2 diabetes mellitus. Diabetes.

Forbes, J. M., & Cooper, M. E. (2013). Mechanisms of diabetic complications. Physiological Reviews.

International Diabetes Federation. (2023). IDF Diabetes Atlas.

Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine.

Neal, B., et al. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEJM.

ERGASHEVA, G. T. (2024). OBESITY AND OVARIAN INSUFFICIENCY. Valeology: International Journal of Medical Anthropology and Bioethics, 2(09), 106-111.

Ergasheva, G. T. (2024). Modern Methods in the Diagnosis of Autoimmune Thyroiditis. American Journal of Bioscience and Clinical Integrity, 1(10), 43-50.

Tokhirovna, E. G. (2024). COEXISTENCE OF CARDIOVASCULAR DISEASES IN PATIENTS WITH TYPE 2 DIABETES. TADQIQOTLAR. UZ, 40(3), 55-62.

Toxirovna, E. G. (2024). DETERMINATION AND STUDY OF GLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH COMORBID DISEASES. TADQIQOTLAR. UZ, 40(3), 71-77.

Toxirovna, E. G. (2024). XOMILADORLIKDA QANDLI DIABET KELTIRIB CHIQARUVCHI XAVF OMILLARINI ERTA ANIQLASH USULLARI. TADQIQOTLAR. UZ, 40(3), 63-70.

Toxirovna, E. G. (2024). QANDLI DIABET 2-TIP VA KOMORBID KASALLIKLARI BO’LGAN BEMORLARDA GLIKEMIK NAZORAT. TADQIQOTLAR. UZ, 40(3), 48-54.

Tokhirovna, E. G. (2024). MECHANISM OF ACTION OF METFORMIN (BIGUANIDE) IN TYPE 2 DIABETES. JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH, 3(5), 210-216.

Tokhirovna, E. G. (2024). THE ROLE OF METFORMIN (GLIFORMIN) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE, 4(4), 171-177.

Эргашева, Г. Т. (2024). Эффект Применения Бигуанида При Сахарным Диабетом 2 Типа И Covid-19. Research Journal of Trauma and Disability Studies, 3(3), 55-61.

Toxirovna, E. G. (2024). QANDLI DIABET 2 TUR VA YURAK QON TOMIR KASALLIKLARINING BEMOLARDA BIRGALIKDA KECHISHI. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 38(7), 202-209.

Эргашева, Г. Т. (2024). СОСУЩЕСТВОВАНИЕ ДИАБЕТА 2 ТИПА И СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У ПАЦИЕНТОВ. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 38(7), 219-226.

Downloads

Published

2026-04-20

How to Cite

Ergasheva Gulshan Tokhirovna. (2026). BREAKTHROUGH THERAPIES IN TYPE 2 DIABETES: ADVANCED ROLE OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS. International Multidisciplinary Journal for Research & Development, 13(4), 882–885. Retrieved from https://ijmrd.in/index.php/imjrd/article/view/5715